{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:17:34Z","timestamp":1789881454141,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T00:00:00Z","timestamp":1446163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T00:00:00Z","timestamp":1446163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA1205621"],"award-info":[{"award-number":["1R01CA1205621"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA63731"],"award-info":[{"award-number":["U01CA63731"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["N01-CN-67009"],"award-info":[{"award-number":["N01-CN-67009"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["N01-PC-35142"],"award-info":[{"award-number":["N01-PC-35142"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10552-015-0689-y","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T09:27:47Z","timestamp":1446197267000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Breast cancer recurrence in relation to antidepressant use"],"prefix":"10.1007","volume":"27","author":[{"given":"Jessica","family":"Chubak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin J. A.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onchee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana S. M.","family":"Buist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,30]]},"reference":[{"key":"689_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-007-9828-9","volume":"112","author":"J Chubak","year":"2008","unstructured":"Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112:123\u2013132. doi:\n                    10.1007\/s10549-007-9828-9","journal-title":"Breast Cancer Res Treat"},{"key":"689_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2330-z","author":"SB Dusetzina","year":"2012","unstructured":"Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL (2012) Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004\u20132010. Breast Cancer Res Treat. doi:\n                    10.1007\/s10549-012-2330-z","journal-title":"Breast Cancer Res Treat"},{"key":"689_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/pon.3606","volume":"24","author":"MJ Fisch","year":"2015","unstructured":"Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI (2015) Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psycho Oncol 24:523\u2013532. doi:\n                    10.1002\/pon.3606","journal-title":"Psycho Oncol"},{"key":"689_CR4","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255\u20132269. doi:\n                    10.1200\/JCO.2013.54.2258","journal-title":"J Clin Oncol"},{"key":"689_CR5","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758\u20131764","journal-title":"J Natl Cancer Inst"},{"key":"689_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1586\/ecp.11.18","volume":"4","author":"DP Cronin-Fenton","year":"2011","unstructured":"Cronin-Fenton DP, Lash TL (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 4:363\u2013377. doi:\n                    10.1586\/ecp.11.18","journal-title":"Expert Rev Clin Pharmacol"},{"key":"689_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30\u201339","journal-title":"J Natl Cancer Inst"},{"key":"689_CR8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4088\/JCP.08r04856blu","volume":"70","author":"JE Desmarais","year":"2009","unstructured":"Desmarais JE, Looper KJ (2009) Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70:1688\u20131697. doi:\n                    10.4088\/JCP.08r04856blu","journal-title":"J Clin Psychiatry"},{"key":"689_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Nat Cancer Inst 104:452\u2013460. doi:\n                    10.1093\/jnci\/djs126","journal-title":"J Nat Cancer Inst"},{"key":"689_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial. J Nat Cancer Inst 104:441\u2013451. doi:\n                    10.1093\/jnci\/djs125","journal-title":"J Nat Cancer Inst"},{"key":"689_CR11","doi-asserted-by":"publisher","first-page":"e76648","DOI":"10.1371\/journal.pone.0076648","volume":"8","author":"DW Lum","year":"2013","unstructured":"Lum DW, Perel P, Hingorani AD, Holmes MV (2013) CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS ONE 8:e76648. doi:\n                    10.1371\/journal.pone.0076648","journal-title":"PLoS ONE"},{"key":"689_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/clpt.2013.186","volume":"95","author":"MA Province","year":"2014","unstructured":"Province MA, Goetz MP, Brauch H et al (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther [Articles] 95:216\u2013227. doi:\n                    10.1038\/clpt.2013.186","journal-title":"Clin Pharmacol Ther [Articles]"},{"key":"689_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00280-014-2453-5","volume":"73","author":"J Mwinyi","year":"2014","unstructured":"Mwinyi J, Vokinger K, Jetter A, Breitenstein U, Hiller C, Kullak-Ublick GA, Trojan A (2014) Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol 73:1181\u20131188. doi:\n                    10.1007\/s00280-014-2453-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"689_CR14","doi-asserted-by":"publisher","unstructured":"Brauch H, Schroth W, Goetz MP, M\u00fcrdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M (2013) Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 31:176\u2013180. doi: \n                    10.1200\/jco.2012.44.6625","DOI":"10.1200\/jco.2012.44.6625"},{"key":"689_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jnci\/djs139","volume":"104","author":"CM Kelly","year":"2012","unstructured":"Kelly CM, Pritchard KI (2012) CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Nat Cancer Inst 104:427\u2013428. doi:\n                    10.1093\/jnci\/djs139","journal-title":"J Nat Cancer Inst"},{"key":"689_CR16","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/jnci\/djs303","volume":"104","author":"CM Kelly","year":"2012","unstructured":"Kelly CM, Pritchard KI (2012) Response. J Nat Cancer Inst 104:1268. doi:\n                    10.1093\/jnci\/djs303","journal-title":"J Nat Cancer Inst"},{"key":"689_CR17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jnci\/djt221","volume":"105","author":"D Berry","year":"2013","unstructured":"Berry D (2013) CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Nat Cancer Inst 105:1267\u20131269. doi:\n                    10.1093\/jnci\/djt221","journal-title":"J Nat Cancer Inst"},{"key":"689_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs312","author":"PD Pharoah","year":"2012","unstructured":"Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. doi:\n                    10.1093\/jnci\/djs312","journal-title":"J Natl Cancer Inst"},{"key":"689_CR19","doi-asserted-by":"publisher","unstructured":"Berry DA (2014) CYP2D6 genotype and adjuvant tamoxifen. Clin Pharmacol Ther [Point\/Counterpoint] 96:138\u2013140. doi:\n                    10.1038\/clpt.2014.96","DOI":"10.1038\/clpt.2014.96"},{"key":"689_CR20","unstructured":"U.S. Food and Drug Administration. Safety: Paxil CR (paroxetine hydrochloride) Controlled-Release Tablets October 2008. Silver Spring, MD: U.S. Food and Drug Administration; 2008. Updated September 24, 2013; cited 2014 December 28. \n                    http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/Safety-RelatedDrugLabelingChanges\/ucm122147.htm"},{"key":"689_CR21","unstructured":"U.S. Food and Drug Administration. Safety: Paxil (paroxetine HCl) tablets, oral solution and Paxil CR tablets. Silver Spring, MD: U.S. Food and Drug Administration; 2011. Updated August 11, 2011; cited 2014 December 28. \n                    http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm233693.htm"},{"key":"689_CR22","doi-asserted-by":"publisher","unstructured":"Ahern TP, Pedersen L, Cronin-Fenton DP, S\u00f8rensen HT, Lash TL (2009) No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 18:2562\u20132564. doi:\n                    10.1158\/1055-9965.epi-09-0516","DOI":"10.1158\/1055-9965.epi-09-0516"},{"key":"689_CR23","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/sj.bjc.6604533","volume":"99","author":"TL Lash","year":"2008","unstructured":"Lash TL, Pedersen L, Cronin-Fenton D et al (2008) Tamoxifen\u2019s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99:616\u2013621","journal-title":"Br J Cancer"},{"key":"689_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.2009.26.7906","volume":"28","author":"TL Lash","year":"2010","unstructured":"Lash TL, Rosenberg CL (2010) Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol 28:1273\u20131275. doi:\n                    10.1200\/JCO.2009.26.7906","journal-title":"J Clin Oncol"},{"key":"689_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10549-010-1008-7","volume":"125","author":"N Siegelmann-Danieli","year":"2011","unstructured":"Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, Loebstein R (2011) Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125:505\u2013510. doi:\n                    10.1007\/s10549-010-1008-7","journal-title":"Breast Cancer Res Treat"},{"key":"689_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1177\/0091270004266618","volume":"44","author":"D Lehmann","year":"2004","unstructured":"Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A (2004) Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol 44:861\u2013865","journal-title":"J Clin Pharmacol"},{"key":"689_CR27","doi-asserted-by":"publisher","unstructured":"Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. doi:\n                    10.1136\/bmj.c693","DOI":"10.1136\/bmj.c693"},{"key":"689_CR28","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2009.25.0894","volume":"28","author":"VO Dezentje","year":"2010","unstructured":"Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H-J (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423\u20132429. doi:\n                    10.1200\/jco.2009.25.0894","journal-title":"J Clin Oncol"},{"key":"689_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/pds.2064","volume":"20","author":"KJ Wernli","year":"2011","unstructured":"Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20:131\u2013137. doi:\n                    10.1002\/pds.2064","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"689_CR30","doi-asserted-by":"publisher","unstructured":"Azoulay L, Dell\u2019Aniello S, Huiart L, du Fort G, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126:695\u2013703. doi:\n                    10.1007\/s10549-010-1162-y","DOI":"10.1007\/s10549-010-1162-y"},{"key":"689_CR31","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903575273","author":"TL Lash","year":"2010","unstructured":"Lash TL, Cronin-Fenton D, Ahern TP et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. doi:\n                    10.3109\/02841860903575273","journal-title":"Acta Oncol"},{"key":"689_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10549-014-2870-5","volume":"144","author":"DM Boudreau","year":"2014","unstructured":"Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144:405\u2013416. doi:\n                    10.1007\/s10549-014-2870-5","journal-title":"Breast Cancer Res Treat"},{"key":"689_CR33","doi-asserted-by":"publisher","unstructured":"Wirtz HS, Buist DS, Gralow JR et al (2013) Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev 22:1588\u20131599. doi:\n                    10.1158\/1055-9965.EPI-13-0454","DOI":"10.1158\/1055-9965.EPI-13-0454"},{"key":"689_CR34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cncr.22472","volume":"109","author":"AM Geiger","year":"2007","unstructured":"Geiger AM, Thwin SS, Lash TL et al (2007) Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109:966\u2013974","journal-title":"Cancer"},{"key":"689_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613\u2013619. doi:\n                    10.1016\/0895-4356(92)90133-8","journal-title":"J Clin Epidemiol"},{"key":"689_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/pds.1119","volume":"14","author":"DM Boudreau","year":"2005","unstructured":"Boudreau DM, Doescher MP, Saver BG, Jackson JE, Fishman PA (2005) Reliability of Group Health Cooperative automated pharmacy data by drug benefit status. Pharmacoepidemiol Drug Saf 14:877\u2013884","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"689_CR37","first-page":"223","volume-title":"Pharmacoepidemiology","author":"KW Saunders","year":"2005","unstructured":"Saunders KW, Davis RL, Stergachis A (2005) Group Health Cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223\u2013239","edition":"4"},{"key":"689_CR38","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1001\/jama.292.13.1581","volume":"292","author":"NL Smith","year":"2004","unstructured":"Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM (2004) Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292:1581\u20131587","journal-title":"JAMA"},{"key":"689_CR39","doi-asserted-by":"crossref","unstructured":"Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48(6) Supplement:S96\u2013S105","DOI":"10.1097\/MLR.0b013e3181d99107"},{"key":"689_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/EDE.0b013e3182961708","volume":"24","author":"J Chubak","year":"2013","unstructured":"Chubak J, Yu O, Buist DS, Wirtz HS, Boudreau DM (2013) Time scale in follow-up studies: considering disease prognosis. Epidemiology 24:628\u2013629. doi:\n                    10.1097\/EDE.0b013e3182961708","journal-title":"Epidemiology"},{"key":"689_CR41","volume-title":"AJCC cancer staging manual","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID, Fritz AG, Balch C, Haller DG, Morrow M (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York","edition":"6"},{"key":"689_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2010.04.015","volume":"67","author":"AI Phipps","year":"2010","unstructured":"Phipps AI, Ichikawa L, Bowles EJA, Carney PA, Kerlikowske K, Miglioretti DL, Buist DSM (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67:60\u201366. doi:\n                    10.1016\/j.maturitas.2010.04.015","journal-title":"Maturitas"},{"key":"689_CR43","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jnci\/djt211","volume":"105","author":"J Chubak","year":"2013","unstructured":"Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS (2013) Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105:1456\u20131462. doi:\n                    10.1093\/jnci\/djt211","journal-title":"J Natl Cancer Inst"},{"key":"689_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10549-012-1963-2","volume":"133","author":"AHB Wu","year":"2012","unstructured":"Wu AHB, Lorizio W, Tchu S et al (2012) Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat 133:677\u2013683. doi:\n                    10.1007\/s10549-012-1963-2","journal-title":"Breast Cancer Res Treat"},{"key":"689_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5665\/sleep.3410","volume":"37","author":"SM Bertisch","year":"2014","unstructured":"Bertisch SM, Herzig SJ, Winkelman JW, Buettner C (2014) National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 37:343\u2013349. doi:\n                    10.5665\/sleep.3410","journal-title":"Sleep"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-015-0689-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0689-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:02:50Z","timestamp":1589659370000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-015-0689-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s10552-015-0689-y","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,30]]},"assertion":[{"value":"21 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ms. Yu has received funding from unrelated research grants awarded to Group Health Research Institute from Amgen and Bayer. Dr. Boudreau has received funding from unrelated research grants awarded to Group Health Research Institute from Amgen, Sanofi Aventis, and Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}